To describe the treatment patterns, cardiac adverse effects and outcomes of Manitoba patients with early stage HER2 positive breast cancer, treated with trastuzumab and an anthracycline versus a non-anthracycline chemotherapy backbone. The gene discussed is ERBB2; the disease is breast cancer.